1. Lead Researcher: Jennifer Soung, M.D.

2. Study Title: A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- And Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA-15406 Ointment, Applied Twice Daily for 28 days, in Adult Subjects With Atopic Dermatitis

3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to find out more about OPA-15406 in people with atopic dermatitis

4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with atopic dermatitis and who are not taking certain prohibited medications

5. Location (if other than UCIMC): Dermatology Clinical Research Center, University of California, Irvine, 1001 Hewitt Hall, Irvine CA 92697

6. Time Commitment (e.g., three one-hour long visits in three weeks): This study will include 8 visits (including a screening visit) and may take up to approximately 32 hours total over a period of approximately 60-72 days. You will take study drug (OPA-15406 or placebo) for approximately 28 days.

7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that OPA-15406 will be better than the standard (usual) treatment, there is no proof of this yet. If you are in the group that receives OPA-15406 and it proves to treat your condition more effectively or with less side effects than the standard treatment, you may benefit from participating in the study, but this cannot be guaranteed

8. Compensation (if any): There are 7 visits total in this study, two visits compensated at $100 each and five visits compensated at $25 each. Total compensation for participation in the entire study is $325.
9. Contact Name, UCI Department, Phone Number and E-mail:
Brian Swasdibutra
UCI Department of Dermatology
949-824-7103
bswasdib@uci.edu

Signature of Lead Researcher: ____________________________ Date: ___________

IRB Approval Granted on: